Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

28 recalls, newest first

Class I · High risk

Atovaquone Oral Suspension

Microbial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.

Terminated Microbial contamination Bionpharma Inc. NDC 69452-252-87 D-0012-2025
Class II · Moderate risk

Decitabine for Injection 50mg per vial

CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-361-40 D-0582-2024
Class I · High risk

suntegrity

Microbial Contamination of Non-Sterile Products: Presence of Aspergillus Sydowii (Mold)

Ongoing Microbial contamination Synchronicity Spa INC, Dba Sunte D-0588-2024
Class II · Moderate risk

Febuxostat Tablets 80mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-060-01 D-0369-2024
Class II · Moderate risk

Febuxostat Tablets 40mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-059-01 D-0368-2024
Class II · Moderate risk

Fexofenadine Hydrochloride Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 51660-998-30 D-0273-2024
Class II · Moderate risk

Niacin Extended-Release Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-539-81 D-0270-2024
Class II · Moderate risk

Niacin Extended-Release Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-613-81 D-0269-2024
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 63304-175-13 D-0268-2024

Recalls by year